Fred Hutch Cancer Center | Strategic Alliance Partners

October 27, 2020

Daniel W. Lin, MD, discusses the role of genomic markers in prostate cancer.

August 31, 2020

Heather Greenlee, ND, PhD, MPH, provides strategies to mitigate the increased risk of cardiovascular disease in women with breast cancer.

August 11, 2020

Scott S. Tykodi, MD, PhD, provides background to the phase 2 KEYNOTE-427 trial with pembrolizumab in renal cell carcinoma.

June 17, 2020

William R. Gwin III, MD, discusses the ongoing trial examining this novel combination and provided insight into the next steps for this research.

June 03, 2020

William R. Gwin III, MD, discusses the safety profile of alpha-tocopheryloxyacetic acid in combination with trastuzumab in recurrent HER2-positive metastatic breast cancer.

May 23, 2020

Jerald P. Radich, MD, discusses measuring minimal residual disease (MRD) in hematologic malignancies.

May 08, 2020

Celestia S. Higano, MD, FACP, discusses the state of immunotherapy in prostate cancer.

April 23, 2020

Elizabeth M. Swisher, MD, discusses the limitations of homologous recombination deficiency as a biomarker of response in ovarian cancer based on findings from the phase III VELIA trial.

April 07, 2020

This OncLive webinar will uncover the latest treatments in myelofibrosis by Bart Scott, MD. Join us on Tuesday, April 28, 2020 or Thursday, April 30, 2020 at 5 PM or 8 PM EDT.

April 07, 2020

Petros Grivas, MD, PhD, discusses potential combination regimens with cabazitaxel in prostate cancer.

April 03, 2020

Jerald P. Radich, MD, discusses the growing importance of MRD assessment in the treatment paradigm for patients with hematologic malignancies.

March 28, 2020

Jerald P. Radich, MD, discusses the utility of minimal residual disease in hematologic malignancies.

March 27, 2020

Petros Grivas, MD, PhD, discusses the role of targeted therapy in prostate cancer.

March 18, 2020

Petros Grivas, MD, PhD, discusses PARP inhibition in patients with germline and somatic DNA damage repair-mutated metastatic castration-resistant prostate cancer.

March 11, 2020

Petros Grivas MD, PhD, discusses biomarker-driven and combination research in metastatic castration-resistant prostate cancer.

March 07, 2020

Petros Grivas, MD, PhD, physician, Seattle Cancer Care Alliance; associate professor, Department of Medicine, Division of Oncology and clinical director of the Genitourinary Cancers Program, University of Washington School of Medicine; and associate member, Clinical Research Division, Fred Hutchinson Cancer Center, discusses the combination of cabazitaxel and enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC).

February 14, 2020

Heather H. Cheng, MD, PhD, discusses the goals of the ongoing GENTleMEN trial in prostate cancer.

January 29, 2020

Andrew J. Cowan, MD, discusses efficacy and safety of BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

January 25, 2020

Heather H. Cheng, MD, PhD, discusses considerations for molecular testing in prostate cancer.

December 23, 2019

Julie R. Gralow, MD, discusses the emergence of biosimilars in the United States and globally.